| ViraferonPeg (peginterferon-α-2b) / Merck (MSD) |
NCT01340573: Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896) |
|
|
| Terminated | N/A | 3 | NA | PegIntron Pen, pegylated interferon Pen, Ribavirin, Ribasphere, Vilona, Copegus, Rebetol, Virazole | Merck Sharp & Dohme LLC | Chronic Hepatitis C | 10/07 | 10/07 | | |
NCT00705107: Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-naïve Adult Patients With Hepatitis C in Romania (Study P04247) |
|
|
| Terminated | N/A | 267 | Europe | PegIntron pen (peginterferon alfa-2b; SCH 54031), SCH 54031, Rebetol (ribavirin; SCH 18908), SCH 18908 | Merck Sharp & Dohme LLC | Hepatitis C, Chronic, Hepatitis C | 11/07 | 11/07 | | |
NCT00704717: Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301) |
|
|
| Completed | N/A | 185 | Europe | PegIntron (peginterferon alfa-2b; SCH 54031) pen, SCH 54031, Rebetol (ribavirin; SCH 18908), SCH 18908 | Merck Sharp & Dohme LLC | Hepatitis C, Chronic, Hepatitis C | 12/07 | 12/07 | | |
NCT00728494: Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671) |
|
|
| Completed | N/A | 99 | Europe | PegIntron (peginterferon alfa-2b; SCH 54031), PegIntron, Rebetol (ribavirin; SCH 18908), Rebetol, Patient Assistance Program, Support program | Merck Sharp & Dohme LLC | Hepatitis C, Chronic, Hepatitis C | 12/07 | 12/07 | | |
| Completed | N/A | 1995 | Europe | Peginterferon alfa-2b (SCH 54031), PegIntron, PegPen, Ribavirin (SCH 18908), Rebetol | Merck Sharp & Dohme LLC | Hepatitis C, Chronic | 04/08 | 04/08 | | |
NCT00705263: Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED) |
|
|
| Completed | N/A | 113 | Europe | Peginterferon alfa-2b (SCH 54031), PegIntron, PegPen, Ribavirin (SCH 18908), Rebetol | Schering-Plough | Hepatitis C, Chronic, Hepacivirus | 05/08 | 05/08 | | |
ADEQUATION, NCT00705666: Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED) |
|
|
| Completed | N/A | 789 | Europe | Peginterferon alfa-2b (SCH 54031), PegIntron, Ribavirin (SCH 18908), Rebetol | Merck Sharp & Dohme LLC | Hepatitis C, Chronic, Hepacivirus | 07/08 | 07/08 | | |
NCT00514111: Factors Associated to Success of Hepatitis C Therapy |
|
|
| Completed | N/A | 100 | RoW | pegylated-interferon, conventional-interferon, ribavirin, Pegasys, PegIntron, Ribavirin | UPECLIN HC FM Botucatu Unesp | Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted | 07/08 | 12/08 | | |
NCT00709228: Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793) |
|
|
| Completed | N/A | 496 | Europe | PegIntron, SCH 054031, Rebetol, SCH 18908 | Merck Sharp & Dohme LLC | Hepatitis C | 11/08 | 11/08 | | |
NCT00724295: Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505) |
|
|
| Completed | N/A | 1077 | Japan | peginterferon alfa-2b, PegIntron, SCH 54031, ribavirin, Rebetol, SCH 18908 | Merck Sharp & Dohme LLC | Hepatitis C, Chronic, Hepatitis C | 12/08 | 12/08 | | |
NCT00724230: Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED) |
|
|
| Completed | N/A | 505 | Japan | PegIntron (peginterferon alfa-2b; SCH 54031), SCH 54031, Rebetol (ribavirin; SCH 18908), SCH 18908 | Merck Sharp & Dohme LLC | Hepatitis C, Chronic, Hepatitis C | 12/08 | 12/08 | | |
SUPPORT, NCT00726557: Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261) |
|
|
| Completed | N/A | 246 | Europe | PegIntron (pegylated interferon alfa-2b; SCH 54031), SCH 54031, Rebetol (ribavirin; SCH 18908), SCH 18908 | Merck Sharp & Dohme LLC | Hepatitis C, Chronic, Substance Abuse, Intravenous | 01/09 | 01/09 | | |
NCT00724373: Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED) |
|
|
| Completed | N/A | 442 | Europe | Peginterferon alfa-2b (SCH 54031), PegIntron, ViraferonPeg, Ribavirin (SCH 18908), Rebetol | Merck Sharp & Dohme LLC | Hepatitis C, Chronic | 02/09 | 02/09 | | |
NCT00704522: Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED) |
|
|
| Completed | N/A | 601 | Europe | Peginterferon alfa-2b (SCH 54031), PegIntron, PegIntron pen, Ribavirin (SCH 18908), Rebetol, Patient assistance program | Merck Sharp & Dohme LLC | Hepatitis C, Chronic, Hepacivirus | 04/09 | 04/09 | | |
NCT00727311: Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED) |
|
|
| Completed | N/A | 2302 | Europe | PegIntron (peginterferon alfa-2b; SCH 54031) injector, SCH 54031, Rebetol (ribavirin; SCH 18908), SCH 18908 | Merck Sharp & Dohme LLC | Hepatitis C, Chronic, Hepatitis C | 06/09 | 06/09 | | |
APEGIN, NCT00724854: Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427) |
|
|
| Completed | N/A | 1146 | RoW | PegIntron (peginterferon alfa-2b; SCH 54031), SCH 54031, Rebetol (ribavirin; SCH 18908), SCH 18908 | Merck Sharp & Dohme LLC | Hepatitis C, Chronic, Hepatitis C | 09/09 | 09/09 | | |
@dhere, NCT00704964: Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413) |
|
|
| Completed | N/A | 746 | Europe | PegIntron, PegIntron pen, peginterferon alfa-2b, SCH 54031, Rebetol, ribavirin, SCH 18908 | Merck Sharp & Dohme LLC | Hepatitis C, Chronic Hepatitis C | 10/09 | 10/09 | | |
NCT00723931: PegIntron Injection Surveillance Plan (Study P04123) |
|
|
| Completed | N/A | 1267 | RoW | Peginterferon alfa-2b (SCH 54031), PegIntron | Merck Sharp & Dohme LLC | Hepatitis C, Chronic | 11/09 | 11/09 | | |
PRACTICE, NCT00709059: Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243) |
|
|
| Completed | N/A | 538 | Europe | PegIntron (peginterferon alfa-2b; SCH 54031), SCH 54031, Rebetol (ribavirin; SCH 18908), SCH 18908 | Merck Sharp & Dohme LLC | Hepatitis C, Chronic | 12/09 | 12/09 | | |
NCT00705224: Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562) |
|
|
| Completed | N/A | 250 | RoW | Pegylated Interferon, PegIntron, (SCH 54031), Ribavirin, Rebetol, (SCH 18908) | Merck Sharp & Dohme LLC | Hepatitis C, Chronic, Hepatitis C Virus | 08/10 | 08/10 | | |
NCT00725205: Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690) |
|
|
| Completed | N/A | 294 | Europe | PegIntron (Peginterferon alfa-2b), PegIntron, SCH 54031, Rebetol (Ribavirin), Rebetol, SCH 18908 | Merck Sharp & Dohme LLC | Hepatitis C, Chronic, Hepatitis C | 10/10 | 10/10 | | |
NCT00724464: Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209) |
|
|
| Completed | N/A | 332 | Europe | PegIntron (peginterferon alfa-2b, pegylated interferon alfa-2b), SCH 54031, Rebetol (ribavirin), SCH 18908 | Merck Sharp & Dohme LLC | Hepatitis C, Chronic, Hepatitis C | 10/10 | 10/10 | | |
ATHENAS, NCT00856024: - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632) |
|
|
| Terminated | N/A | 902 | RoW | Peginterferon alfa-2b, SCH 54031, Ribavirin, SCH 18908 | Merck Sharp & Dohme LLC | Hepatitis C, Chronic | 10/10 | 10/10 | | |
NCT00723632: Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED) |
|
|
| Completed | N/A | 901 | Europe | peginterferon alfa-2b, SCH 054031, PegIntron, peginterferon α-2b, ribavirin, SCH 018908, Rebetol | Merck Sharp & Dohme LLC | Hepatitis C, Chronic, Hepatitis C | 12/10 | 12/10 | | |
NCT00725751: Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255) |
|
|
| Completed | N/A | 353 | Europe | Pegylated interferon alfa-2b (PegIFN-2b), PegIntron, SCH 54031, Ribavirin, Rebetol, SCH 18908 | Merck Sharp & Dohme LLC | Hepatitis C, Chronic | 03/11 | 03/11 | | |
RE-CHUT, NCT00725842: Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed) |
|
|
| Terminated | N/A | 97 | Europe | Peg-IFN alfa-2b, SCH 054031, Ribavirin, SCH 018908 | Merck Sharp & Dohme LLC | Hepatitis C, Hepatitis C, Chronic | 06/11 | 06/11 | | |
NCT01054742: Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2) |
|
|
| Completed | N/A | 2 | RoW | Standard of Care PegIntron, peginterferon alfa-2b, PEG2b, SCH 054031, Standard of Care Ribavirin, REBETOL;, SCH 018908 | Merck Sharp & Dohme LLC | Hepatitis C | 06/11 | 06/11 | | |
MEN_EPID, NCT01402583: Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C |
|
|
| Completed | N/A | 1000 | Europe | PEG IFN/Ribavirin, Pegylated IFN 2a Pegasys, Pegylated IFN 2b PegIntron, Copegus, Rebetol | Prof. Facchinetti Fabio, Merck Sharp & Dohme LLC | Chronic Hepatitis C | 08/11 | 09/11 | | |
NCT00724451: Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1) |
|
|
| Completed | N/A | 1128 | Europe | Peginterferon alfa-2b, SCH 054031, PegIntron, Ribavirin, SCH 018908, Copegus, Rebetol, Virazole, RBV, Peginterferon alfa-2a, Pegasys | Merck Sharp & Dohme LLC | Hepatitis C, Hepatitis C, Chronic | 10/11 | 10/11 | | |
POMOSCH, NCT01098097: Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011) |
|
|
| Completed | N/A | 963 | RoW | Peginterferon alpha, PegIntron, SCH 054031, MK-4031, Ribavirin, Rebetol, SCH 018908, MK-8908 | Merck Sharp & Dohme LLC | Hepatitis C, Chronic | 10/11 | 10/11 | | |
NCT00736242: Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584) |
|
|
| Completed | N/A | 232 | Europe | PEG-IFN alfa-2b, SCH 054031, PegIntron, RBV, Rebetol, SCH 018908 | Merck Sharp & Dohme LLC | Chronic Hepatitis C, Hepatitis C, HIV Infections | 12/11 | 12/11 | | |
MK-4031-267, NCT00724893: Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423) |
|
|
| Completed | N/A | 2430 | Canada | PegIFN-2b, Pegetron®, Pegylated interferon alfa-2b, PegIntron, SCH 054031, Ribavirin, SCH 018908 | Merck Sharp & Dohme LLC | Hepatitis C, Chronic, Hepatitis C | 08/12 | 08/12 | | |
VIDA, NCT00863109: Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336) |
|
|
| Completed | N/A | 133 | NA | Peginterferon alfa-2b (PEG), PegIntron, SCH 054031, Ribavirin (RBV), Rebetol, SCH 18908 | Merck Sharp & Dohme LLC | Hepatitis C, Chronic, Genotype 1, HCV-1 | 05/13 | 05/13 | | |
NCT01625793: Inflammation, Stress & Social Behavior: Using Ecological Assessments & Model Systems to Enhance Relevance to Health Outcomes |
|
|
| Withdrawn | N/A | 0 | US | Interferon-alpha, Pegintron®, Schering Plough, PEGASYS®, Roche | University of Arizona, Emory University, National Center for Complementary and Integrative Health (NCCIH) | Hepatitis C | 07/13 | 07/13 | | |
